Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials
Claire Gallois(Université Paris Cité), Julien Taı̈eb(Hôpital Européen Georges-Pompidou), Ioannis Boukovinas, Steven R. Alberts(North Central Cancer Treatment Group), Jeffrey A. Meyerhardt(CancerCare), Demetris Papamichael(Bank of Cyprus Oncology Center), Qian Shi(Mayo Clinic), Sara Lonardi(Istituto Oncologico Veneto), Aimery de Gramont(Institut Hospitalier Franco Britannique), Timothy Iveson(University Hospital Southampton NHS Foundation Trust), Caroline Kelly(Cancer Research UK), Greg Yothers(University of Pittsburgh), Takayuki Yoshino(University of Tsukuba), Eiji Oki(Kyushu University), Frank A. Sinicrope(Mayo Clinic in Arizona), Anthony F. Shields(Wayne State University), Thierry André(Inserm), Ioannis Souglakos(University of Crete), Richard M. Goldberg(Ontario Institute for Cancer Research), Roberto Labianca(Ospedale Papa Giovanni XXIII), Alberto F. Sobrero(Ospedale Policlinico San Martino), Rachel Kerr(Cancer Research UK Clinical Trials Unit), Jeffrey P. Meyers(Mayo Clinic in Florida), Daniel G. Haller(University of Pennsylvania)
Cited by 50
Related Papers
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
|New England Journal of Medicine|2020|2.9k